Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Kalaris Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 80 | 1 | 84 | +5 |
| Shares | 25.6M | 324.7K | 25.4M | +219.7K (+0.9%) |
| Value | $640.3M | $8.14M | $329.4M | −$302.7M (−47.9%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 327,679 | $4.24M | 0.01% |
| Gsa Capital Partners LLP | 109,607 | $1.42M | 0.18% |
| Millennium Management LLC | 69,599 | $901.0K | 0.00% |
| Citadel Advisors LLC | 60,115 | $778.0K | 0.00% |
| Dimensional Fund Advisors LP | 49,050 | $635.0K | 0.00% |
| Trexquant Investment LP | 35,614 | $461.0K | 0.03% |
| Tudor Investment Corp Et Al | 24,683 | $319.0K | 0.01% |
| Price T Rowe Associates Inc | 20,575 | $266.0K | 0.00% |
| Squarepoint Ops LLC | 15,292 | $198.0K | 0.00% |
| Walleye Trading LLC | 14,462 | $187.0K | 0.00% |
| Two Sigma Advisers, LP | 12,900 | $167.0K | 0.00% |
| Ensign Peak Advisors, Inc | 5,750 | $74.0K | 0.00% |
| Point72 Hong Kong Ltd | 1,479 | $19.0K | 0.00% |
| Carroll Financial Associates, Inc. | 1,000 | $13.0K | 0.00% |
| CWM, LLC | 934 | $12.0K | 0.00% |
| Group One Trading, L.P. | 200 | $3.00K | 0.00% |
| Investmark Advisory Group LLC | 200 | $2.00K | 0.00% |
| Covestor Ltd | 21 | $0 | 0.00% |
Sold out (13)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Wellington Management Group LLP | 267,996 | $6.72M |
| ArrowMark Colorado Holdings LLC | 125,000 | $3.13M |
| Endurant Capital Management LP | 44,430 | $1.11M |
| ExodusPoint Capital Management, LP | 15,871 | $398.0K |
| SG Americas Securities, LLC | 15,251 | $382.0K |
| Jump Financial, LLC | 15,227 | $381.0K |
| Parametric Portfolio Associates LLC | 12,490 | $313.0K |
| Arizona State Retirement System | 9,754 | $244.0K |
| Nisa Investment Advisors, LLC | 4,500 | $113.0K |
| Amundi | 1,470 | $37.0K |
| Penserra Capital Management LLC | 1,485 | $37.0K |
| Harbour Investments, Inc. | 15 | $0 |
| Ellevest, Inc. | 9 | $0 |
Not filed for Q4 2021 yet (1)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Marshall Wace North America L.P. | 324,658 | $8.14M |